Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Conditions
Interventions
Intervention1: Lorlatinib (PF-06463922): 100 mg orally QD, with or without food, until disease progression, unacceptable toxicity, or participant refusal/lost to follow-up.
Control Intervention1: Not
Sponsors
Pfizer Inc
Pfizer Products India Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: (1)Evidence of histologically or cytologically confirmed diagnosis of unresectable advanced and/or recurrent NSCLC that carries an ALK rearrangement, as detected by an appropriate test. (2)Disease progression or intolerance to 1 previous treatment with ALK TKI. Participants may have also had prior chemotherapy for their advanced and/or recurrent disease. (3)Participants with asymptomatic CNS metastases (including participants controlled with stable or decreasing steroid use within the last 2 weeks prior to study enrollment) will be eligible. (4)Age ââ?°Â¥18 years. (5)ECOG performance status (PS) 0, 1, or 2. (6)Adequate hematologic and renal function as defined (7)Adequate liver function, including: Total serum bilirubin ââ?°Â¤1.5 Ã?â?? upper limit of normal (ULN); AST & ALT ââ?°Â¤2.5 Ã?â?? ULN (ââ?°Â¤5.0 Ã?â?? ULN in case of liver metastases). (8)Adequate pancreatic function, including: Serum total amylase ââ?°Â¤1.5 Ã?â?? ULN; Serum lipase (9)Acute effects of any prior therapy resolved to baseline severity or to CTCAE Grade (10)Systemic anticancer therapy completed within a minimum of 5 half-lives of study enrollment (11)Pregnancy test for females of childbearing potential negative at Screening or female participants who are not of childbearing potential. Male and female participants of childbearing potential and at risk for pregnancy must agree to use a highly effective method of contraception from the time of Screening, throughout the study and for 3 months after the last dose of assigned treatment, 6 months if female participants.
Exclusion criteria
Exclusion criteria: (1)Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study enrollment. Palliative radiation ( 25% of the bone marrow. (2)Major surgery within 4 weeks prior to enrollment. Minor surgical procedures (eg, port insertion) are not excluded, but sufficient time should have passed for adequate wound healing. (3)Known prior or suspected severe hypersensitivity to study drug or any component in its formulation. (4)Active and clinically significant bacterial, fungal, or viral infection. (5)Clinically significant vascular (both arterial and venous) and non-vascular cardiac conditions (active or within 3 months prior to enrollment) (6)History or known presence of interstitial fibrosis, interstitial lung disease (ILD), pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and pulmonary fibrosis. (7)Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the participant inappropriate for enrollment in this study. (8)Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in situ cervical cancer, papillary thyroid cancer, ductal carcinoma in situ [DCIS] of the breast or localized and presumed cured prostate cancer) within the last 3 years prior to enrollment. (9)Concurrent use of any of the following food or drugs (consult the Sponsor if in doubt whether a food or a drug falls into any of the categories described below) within 12 days prior to the first dose of Lorlatinib: (10)Known strong cytochrome (CYP)3A inducers (eg, carbamazepine, enzalutamide, mitotane, rifampin, St. Johnââ?¬•s Wort). (11)Known strong CYP3A inhibitors (eg, grapefruit juice or grapefruit/grapefruit related citrus fruits [eg, Seville oranges, pomelos], boceprevir, cobicistat, clarithromycin, conivaptan, diltiazem, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nelfinavir, paritaprevir, posaconazole, ritonavir alone and with elvitegravir or indinavir or lopinavir or paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir, telaprevir and voriconazole). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed. (12)Known CYP3A substrates with narrow therapeutic index, such as pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl (including transdermal patch) or ergot alkaloids (ergotamine, dihydroergotamine). (13)Known permeability glycoprotein (P-gp) substrates with a narrow therapeutic index (eg, digoxin). (14)Participation in other studies involving investigational drug(s) (Phases 1-4) during study participation. (15)Breastfeeding female participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events (AEs).Timepoint: From the time of first dose to at most 35 days post last dosing date or the date of initiation of a new anticancer therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of response(DoR)Timepoint: From time of first response until progression is met, death or subsequent anticancer therapy is administered;Intracranial duration of response (IC-DoR)Timepoint: From time of first response until progression is met, death or subsequent anticancer therapy is administered;Percentage of Participants with Intracranial Objective Responses based on Investigatorsââ?¬â?¢ assessmentsTimepoint: From time of first dose (Day 1) until progression is met, death or subsequent anticancer therapy is administered.;Percentage of Participants with Objective Responses based on Investigatorsââ?¬â?¢ assessmentsTimepoint: From time of first dose (Day 1) until progression is met, death or subsequent anticancer therapy is administered. | — |
Countries
India
Contacts
Public ContactDr Seema Pai
Pfizer Products India Private Limited
Outcome results
None listed